Searching map area
Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab
? TBD
scientific article published on 4 February 2011
Join to rate
Ratings 0
Nobody has rated this yet. Be the first!
Lists 0
Join to rate
Instance of
Scholarly article
Author
Martino Introna
Josée Golay
Subject
Lymphocyte
Antibody
Leukemia
Rituximab
Whole blood
Monoclonal antibody
References
Wikidata